


Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 304142000201	Application Number To Be Assigned
	Applicant  Malaya Chatterjee et al. <b>09/293533</b>	
	Filing Date Herewith	Group Art Unit To Be Assigned

**ATTACHMENT # 3**

**U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
LCS	1.	08/05/97	5,653,977	Saleh	—	—	
LCA	2.	06/23/87	4,675,287	Reisfeld et al.	—	—	
LCA	3.	09/15/87	4,693,966	Houghton et al.	—	—	
LCA	4.	02/02/88	4,722,840	Valenzuela et al.	—	—	
LCA	5.	07/18/89	4,849,509	Thurin et al.	—	—	
LCA	6.	02/27/90	4,904,596	Hakomori	—	—	
LCA	7.	04/17/90	4,918,164	Hellstrom et al.	—	—	
LCA	8.	04/23/91	5,009,995	Albino et al.	—	—	
LCA	9.	10/01/91	5,053,224	Koprowski et al.	—	—	
LCA	10.	10/15/91	5,057,540	Kensil et al.	—	—	
LCA	11.	02/25/92	5,091,177	Hellstrom et al.	—	—	
LCA	12.	04/07/92	5,102,663	Livingston et al.	—	—	
LCA	13.	07/28/92	5,134,075	Hellstrom et al.	—	—	
LCA	14.	08/25/92	5,141,742	Brown et al.	—	—	
LCA	15.	05/04/93	5,208,146	Irie	—	—	
LCA	16.	08/31/93	5,240,833	Nudelman et al.	—	—	
LCA	17.	09/07/93	5,242,824	Hellstrom et al.	—	—	
LCA	18.	12/14/93	5,270,202	Raychaudhuri	—	—	
LCA	19.	05/03/94	5,308,614	Hakomori	—	—	
LCA	20.	06/25/96	5,529,922	Chapman et al.	—	—	
LCA	21.	11/05/96	5,571,900	Wiegand et al.	—	—	
LCA	22.	03/18/97	5,612,030	Chatterjee et al.	—	—	

EXAMINER: 	DATE CONSIDERED: <b>2/13/02</b> <b>10/30/00</b>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Docket Number 304142000201	Application Number To Be Assigned
	Applicant Malaya Chatterjee et al. <b>09/293533</b>	
	Filing Date Herewith	Group Art Unit To Be Assigned


## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
LH	23.	02/13/86	WO 86/00909	PCT	—	—		
↓	24.	05/16/90	0368131	Europe	↓	↓		
	25.	11/12/92	WO 92/19266	PCT				
	26.	09/08/93	0280209	Europe				
	27.	08/04/94	WO 94/16731	PCT				
	28.	10/13/94	WO 94/22479	PCT				
	29.	02/16/95	WO 95/04548	PCT				
	30.	07/05/95	0661061	Europe	↓	↓		
↓	31.	12/21/95	WO 95/34638	PCT	↓	↓		
LH	32.	07/25/96	WO 96/22373	PCT	—	—		

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
LH	33.	Derwent® Survey of EP 0368131 (05/16/90).
↓	34.	1A7 Heavy Chain Protein Genbank Search. <b>1995</b>
	35.	1A7 Light Chain Protein Genbank Search. <b>1995</b>
	36.	1A7 Heavy Chain DNA Genbank Search. <b>1995</b>
	37.	1A7 Light Chain DNA Genbank Search. <b>1995</b>
	38.	Angeles et al., "Isoabzymes: Structurally and mechanistically similar catalytic antibodies from the same immunization" <u>Biochemistry</u> (1993) <u>32</u> :12128-12135.
	39.	Bhattacharya-Chatterjee et al., "Anti-idiotypic antibodies as potential therapeutic agents for human breast cancer" <u>In Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, Conference on Breast Cancer Therapy Immunology</u> , R.L. Ceriani (Ed.), Plenum Press, N.Y., pages 139-148, 1994.
↓	40.	Bhattacharya-Chatterjee et al., "Idiotypic vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes" <u>J. Immunol.</u> (1987) <u>139</u> :1354-1360.
LH	41.	Bhattacharya-Chatterjee et al., "Idiotypic vaccines against human T-cell leukemia" <u>J. Immunol.</u> (1988) <u>141</u> :1398-1403.

EXAMINER: 	DATE CONSIDERED: <b>2/13/02</b>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned  <div style="text-align: right; font-size: 1.2em;">09/253533</div>
Applicant  <div style="text-align: right;">Malaya Chatterjee et al.</div>		Filing Date Herewith  Group Art Unit To Be Assigned	
<b>OTHER DOCUMENTS</b> <span style="float: right; font-size: 0.8em;">(including author, title, Date, Pertinent Pages, Etc.)</span>			
Examiner Initials	Ref. No.	Title	
LA	42.	Bhattacharya-Chatterjee et al., "Idiotypic antibody immunotherapy of cancer" <u>Cancer Immunol. Immunother.</u> (1994) 38:75-82.	
	43.	Bhattacharya-Chatterjee et al., "Murine monoclonal anti-idiotypic antibody as a potential network antigen for human carcinoembryonic antigen" <u>J. Immunol.</u> (1990) 145:2758-2765.	
	44.	<del>Bhattacharya-Chatterjee et al., "Syngeneic monoclonal anti-idiotypic antibodies against a monoclonal antibody to human melanoma-associated antigen" <u>J. Immunol.</u> (1993) 150:142A (Abstract 805).</del>	
	45.	Bird et al., "Single-chain antigen-binding proteins" <u>Science</u> (1988) 242:423-426.	
	46.	Blier et al., "A limited number of B cell lineages generates the heterogeneity of a secondary immune response" <u>J. Immunol.</u> (1987) 139:3996-4006.	
	47.	Chakraborty et al., "Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotypic antibody" <u>Cancer Res.</u> (1995) 55:1525-1530.	
	48.	Chapman et al., "Induction of IgG antibodies against G <sub>D2</sub> ganglioside in rabbits by an anti-idiotypic monoclonal antibody" <u>J. Clin. Invest.</u> (1991) 88:186-192.	
	49.	Charbonnier et al., "Structural convergence in the active sites of a family of catalytic antibodies" <u>Science</u> (1997) 275:1140-1142.	
	50.	Chattopadhyay et al., "Murine monoclonal anti-idiotypic antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys" <u>Proc. Natl. Acad. Sci. USA</u> (1992) 89:2684-2688.	
	51.	Cheresh et al., "Biosynthesis and expression of the disialoganglioside G <sub>D2</sub> , a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytotoxicity" <u>Cancer Res.</u> (1996) 46:5112-5118.	
	52.	Cheresh et al., "Disialoganglioside G <sub>D2</sub> and G <sub>D3</sub> are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins" <u>J. Cell. Biol.</u> (1986) 102:688-696.	
	53.	Cheresh et al., "Disialoganglioside GD <sub>2</sub> distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin" <u>J. Cell. Biol.</u> (1986) 102:1887-1897.	
	54.	Cheresh et al., "Localization of the gangliosides G <sub>D2</sub> and G <sub>D3</sub> in adhesion plaques and on the surface of human melanoma cells" <u>Proc. Natl. Sci. USA</u> (1984) 81:5767-5771.	
	55.	Cheung et al., "Antibody response to murine anti-G <sub>D2</sub> monoclonal antibodies: correlation with patient survival" <u>Cancer Res.</u> (1994) 54:2228-2233.	
	56.	<del>Cheung et al., "Disialoganglioside G<sub>D2</sub> anti-idiotypic monoclonal antibodies" <u>Int. J. Cancer</u> (1993) 54:499-505.</del>	
HM	57.	Cheung et al., "Ganglioside G <sub>D2</sub> specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma" <u>J. Clin. Oncol.</u> (1987) 5(9):1430-1440.	
EXAMINER:		DATE CONSIDERED: 2/13/02	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned  <div style="text-align: right; font-size: 1.2em;">09/293533</div>	
Applicant  <div style="text-align: right;">Malaya Chatterjee et al.</div>		Filing Date Herewith  Group Art Unit To Be Assigned		
<b>OTHER DOCUMENTS</b> <span style="float: right;"><i>(including author, title, Date, Pertinent Pages, Etc.)</i></span>				
Examiner Initials	Ref. No.	Title		
	58.	Cochran et al., "In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals" <u>J. Virol.</u> (1985) 54:30-37.		
	59.	Conry et al., "A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity" <u>Gene Therapy</u> (1995) 2:59-65.		
	60.	Foon et al., "Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine" <u>J. Clin. Invest.</u> (1995) 96:334-342.		
	61.	Foon et al., "Anti-idiotypic antibodies: novel therapeutic approach to cancer therapy" <u>Immunology Series</u> (1994) 61:281-292.		
	62.	Guo et al., "Mechanistically different catalytic antibodies obtained from immunization with a single transition-state analog" <u>Proc. Natl. Acad. Sci. USA</u> (1995) 92:1694-1698.		
	63.	Hamilton et al., "Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography" <u>Int. J. Cancer</u> (1993) 53:566-573.		
	64.	Hamilton et al., "Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin" <u>Proc. Am. Assoc. Cancer Res.</u> (1993) 34:491 (Abstract 2928).		
	65.	Handgretinger et al., "A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a" <u>Cancer Immunol. Immunother.</u> (1992) 35:199-204.		
	66.	Hastings et al., "Production and characterization of a murine/human chimeric anti-idiotypic antibody that mimics ganglioside" <u>Cancer Res.</u> (1992) 52:1681-1686.		
	67.	Hawkins et al., "A genetic approach to idiotypic vaccination" <u>J. Immunother.</u> (1993) 14:273-278.		
	68.	Hawkins et al., "Plasmid vaccination against B-cell lymphoma" <u>Cancer Gene Therapy</u> (1994) 1(3):208.		
	69.	Heidenheim et al., "CDw60, which identifies the acetylated form of GD <sub>3</sub> gangliosides, is strongly expressed in human basal cell carcinoma" <u>Brit. J. Dermatol.</u> (1995) 133:392-397.		
	70.	Helling et al., "Ganglioside conjugate vaccines" <u>Mol. Chem. Neuropath.</u> (1994) 21:299-309.		
	71.	Hruby et al., "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene" <u>Proc. Natl. Acad. Sci. USA</u> (1983) 80:3411-3415.		
	72.	<u>Imclone Systems Incorporated Annual Report, 1995.</u>		
	73.	Irie et al., "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2" <u>Proc. Natl. Acad. Sci. USA</u> (1986) 83:8694-8698.		
	74.	Kanda et al., "Both V <sub>H</sub> and V <sub>L</sub> regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM <sub>3</sub> " <u>Cell Biophys.</u> (1994) 24/25:65-74.		
	75.	Kaufman et al., "A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)" <u>Int. J. Cancer</u> (1991) 48:900-906.		
	EXAMINER:		DATE CONSIDERED: 2/13/02	
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned  <div style="text-align: right; font-size: 1.2em;">09/293533</div>
Applicant  <div style="text-align: right;">Malaya Chatterjee et al.</div>		Filing Date Herewith	
Group Art Unit To Be Assigned			

OTHER DOCUMENTS <span style="float: right; font-size: 0.8em;">(including author, title, Date, Pertinent Pages, Etc.)</span>		
Examiner Initials	Ref. No.	Title
LW	76.	Leahy et al., "Sequences of 12 monoclonal anti-dinitrophenyl spin-label antibodies for NMR studies" <u>Proc. Natl. Acad. Sci. USA</u> (1988) 85:3661-3665.
	77.	Livingston et al., "GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3" <u>Vaccine</u> (1993) 11(12):1199-1204.
	78.	Livingston, "Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines" <u>Immunol. Rev.</u> (1995) 145:147-166.
	79.	Mittelman et al., "Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma" <u>Proc. Natl. Acad. Sci. USA</u> (1992) 89:466-470.
	80.	Mittelman et al., "Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23" <u>Cancer Research</u> (1994) 54:415-421.
	81.	Miyashita et al., "A common ancestry for multiple catalytic antibodies generated against a single transition-state analog" <u>Proc. Natl. Acad. Sci. USA</u> (1994) 91:6045-6049.
	82.	Moss, "Vaccinia virus: A tool for research and vaccine development" <u>Science</u> (1991) 252:1662-1667.
	83.	Mujoo et al., "Disialoganglioside G <sub>D2</sub> on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytotoxicity and suppression of tumor growth" <u>Cancer Res.</u> (1987) 47:1098-1104.
	84.	Mujoo et al., "Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside G <sub>D2</sub> antibody 14.18" <u>Cancer Res.</u> (1989) 49:2857-2861.
	85.	Nahmias et al., "The immune response toward $\beta$ -adrenergic ligands and their receptors. VIII. Extensive diversity of V <sub>H</sub> and V <sub>L</sub> genes encoding anti-alprenolol antibodies" <u>J. Immunol.</u> (1988) 140:1304-1311.
	86.	Posnett et al., "A novel method for producing anti-peptide antibodies" <u>J. Biol. Chem.</u> (1988) 263:1719-1725.
J	87.	Qin et al., "Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine" <u>Gene Therapy</u> (1996) 3:59-66.
LW	88.	Reininger et al., "Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: Skin vasculitis and glomerulonephritis arise from distinct pathogenic mechanisms" <u>Proc. Natl. Acad. Sci. USA</u> (1990) 87(24):10038-10042.

EXAMINER:	DATE CONSIDERED: 2/13/02
-----------	--------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned  <div style="text-align: right; font-size: 1.2em;">09 293/333</div>
Applicant  <div style="text-align: right;">Malaya Chatterjee et al.</div>		Filing Date Herewith  Group Art Unit To Be Assigned	
<b>OTHER DOCUMENTS</b> <span style="float: right;"><i>(including author, title, Date, Pertinent Pages, Etc.)</i></span>			
Examiner Initials	Ref. No.	Title	
LJ	89.	Russell et al., "Plasmid vaccination to elicit anti-idiotypic immune responses against surface immunoglobulin-positive B-cell malignancies" <u>Brit. J. Haematology</u> (1994) 86(No. Suppl. 1):74 (Abstract P146).	
	90.	<del>Saleh et al., "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen" <u>J. Immunol.</u> (1993) 151(6):3390-3398.</del>	
	91.	Saleh et al., "Phase I trial of the murine monoclonal anti-G <sub>D2</sub> antibody 14G2a in metastatic melanoma" <u>Cancer Res.</u> (1992) 52:4342-4347.	
	92.	Seaver, "Monoclonal antibodies in industry: More difficult than originally thought" <u>Genetic Engineering News</u> (August 1994) pp. 10, 21.	
	93.	Sen et al., "Induction of IgG antibodies by an anti-idiotypic antibody mimicking disialoganglioside GD2" Galley Proof of article accepted for publication in <u>J. Immunother.</u> (1997), 9 pages total.	
	94.	Sen et al., "Murine monoclonal antibody-idiotype antibody breaks tolerance and induces specific antibody response to human disialoganglioside GD2 in cynomolgus monkeys" <u>Abstract presented at the 9th International Congress of Immunology</u> , San Francisco, California, July 23-29, A5250, page 885, 1995.	
	95.	Sen et al., "Murine monoclonal anti-idiotypic (Id) antibody induces specific humoral responses to the GD2 ganglioside in melanoma patients" <u>Abstract submitted for AAAAI/AAI/CIS Joint Meeting, 1997.</u>	
	96.	Spooner et al., "DNA vaccination for cancer treatment" <u>Gene Therapy</u> (1995) 2:173-180.	
	97.	Stenzel-Poore et al., "Clonal diversity, somatic mutation, and immune memory to phosphocholine-keyhole limpet hemocyanin" <u>J. Immunol.</u> (1989) 143:4123-4133.	
	98.	Tam, "High-density multiple antigen-peptide system for preparation of antipeptide antibodies" <u>Methods Enzymol.</u> (1989) 168:7-15.	
	99.	Tang et al., "Genetic immunization is a simple method for eliciting an immune response" <u>Nature</u> (1992) 356:152-154.	
	100.	Tsuchida et al., "Gangliosides of human melanoma" <u>J. Natl. Cancer Inst.</u> (1987) 78:45-54.	
V	101.	Wang et al., "Immunization by direct DNA inoculation induces rejection of tumor cell challenge" <u>Human Gene Therapy</u> (1995) 6:407-418.	
BQ	102.	Yamamoto et al., "Anti-idiotypic monoclonal antibody carrying the internal image of ganglioside GM3" <u>J. Natl. Cancer Inst.</u> (1990) 82(22):1757-1760.	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;">           EXAMINER:  </div> <div style="width: 45%;">           DATE CONSIDERED: 2/13/02         </div> </div>			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			